208 related articles for article (PubMed ID: 9137523)
41. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury.
Saleh S; Ain-Shoka AA; El-Demerdash E; Khalef MM
Chemotherapy; 2009; 55(6):399-406. PubMed ID: 19955745
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
44. Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo.
Serpeloni JM; Batista BL; Angeli JP; Barcelos GR; Bianchi Mde L; Barbosa F; Antunes LM
J Toxicol Environ Health A; 2013; 76(6):345-53. PubMed ID: 23557233
[TBL] [Abstract][Full Text] [Related]
45. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.
Johnsson A; Höglund P; Grubb A; Cavallin-Ståhl E
Cancer Chemother Pharmacol; 1996; 39(1-2):25-33. PubMed ID: 8995496
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of hypotonic cisplatin chemotherapy administered into the peritoneal and the pleural cavities in experimental model.
Katano K; Tsujitani S; Oka S; Saito H; Gomyo Y; Kondo A; Ikeguchi M; Maeta M; Kaibara N
Anticancer Res; 2000; 20(3A):1603-7. PubMed ID: 10928078
[TBL] [Abstract][Full Text] [Related]
47. [Studies on protective effect of selenium on the nephrotoxicity of cis-diamminedichloroplatinum (CDDP) in mice].
Araya Y
Hokkaido Igaku Zasshi; 1990 May; 65(3):245-53. PubMed ID: 2165995
[TBL] [Abstract][Full Text] [Related]
48. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
49. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
Zhang JS; Imai T; Suenaga A; Otagiri M
Int J Pharm; 2002 Jun; 240(1-2):23-31. PubMed ID: 12062498
[TBL] [Abstract][Full Text] [Related]
50. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
51. Assessment of cisplatin-induced kidney injury using an integrated rodent platform.
Chen Y; Brott D; Luo W; Gangl E; Kamendi H; Barthlow H; Lengel D; Fikes J; Kinter L; Valentin JP; Bialecki R
Toxicol Appl Pharmacol; 2013 May; 268(3):352-61. PubMed ID: 23415679
[TBL] [Abstract][Full Text] [Related]
52. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice.
Araújo JG; Mota Ld; Leite EA; Maroni Lde C; Wainstein AJ; Coelho LG; Savassi-Rocha PR; Pereira MT; de Carvalho AT; Cardoso VN; De Oliveira MC
Exp Biol Med (Maywood); 2011 Jul; 236(7):808-15. PubMed ID: 21685237
[TBL] [Abstract][Full Text] [Related]
53. Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats.
Okada A; Fukushima K; Fujita M; Nakanishi M; Hamori M; Nishimura A; Shibata N; Sugioka N
Biol Pharm Bull; 2017; 40(11):1948-1955. PubMed ID: 29093343
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
[TBL] [Abstract][Full Text] [Related]
55. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
Izumi T
Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.
Katano K; Tsujitani S; Maeta M; Fukuda K; Oka S; Hisamitsu K; Ikeguchi M; Kaibara N
Oncol Rep; 2001; 8(3):605-9. PubMed ID: 11295088
[TBL] [Abstract][Full Text] [Related]
57. In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs.
Yin JX; Wei Z; Xu JJ; Sun ZQ
Cancer Chemother Pharmacol; 2015 Sep; 76(3):525-36. PubMed ID: 26183605
[TBL] [Abstract][Full Text] [Related]
58. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
59. L-methionine antagonism of cis-platinum nephrotoxicity.
Basinger MA; Jones MM; Holscher MA
Toxicol Appl Pharmacol; 1990 Mar; 103(1):1-15. PubMed ID: 2315922
[TBL] [Abstract][Full Text] [Related]
60. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.
Uchino H; Matsumura Y; Negishi T; Koizumi F; Hayashi T; Honda T; Nishiyama N; Kataoka K; Naito S; Kakizoe T
Br J Cancer; 2005 Sep; 93(6):678-87. PubMed ID: 16222314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]